At a glance
ClinicalIndex Comparison RecordN/ACompleted· 219,483 enrolled
Drug / intervention
Paclitaxel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Vascular Quality Initiative (VQI) - Data Extraction and Longitudinal Trend Analysis (DELTA) Paclitaxel Device Safety Analysis - Phase I Study
In Brief
An observational study evaluating Paclitaxel and Non-drug coated Device Treatment for Peripheral Vascular Disease. Completed, enrolled 219,483 participants across 1 site.
Detailed Summary
The VQI-DELTA Paclitaxel Device Safety Analysis seeks to assess the comparative safety of paclitaxel coated balloons and stents in the treatment of peripheral artery disease (PAD) through analysis of the VQI Peripheral Vascular Intervention (PVI) registry module using the DELTA system.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Vascular Disease
CountriesUnited States
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJan 2017
Primary CompletionAug 2019
First PostedOct 2019
Study CompletionApr 2020
TodayJul 2026
First PostedOct 1, 2019
Enrollment StartJan 1, 2017
Primary CompletionAug 30, 2019
Study CompletionApr 1, 2020
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 6.8 years ago
Interventions
Paclitaxeldrug
Paclitaxel to treat peripheral arterial disease
Non-drug coated Device Treatmentdevice